Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Among other things, international students seek connections and advice on how to better compete by supporting community groups.
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
2.
A new drug delivery system may help patients with a rare eye cancer
3.
Kate Middleton Gives Cancer Update
4.
Patients with head and neck cancer who cannot receive cisplatin now have new hope.
5.
A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.
1.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
2.
Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management
3.
Overcoming Immunotherapy Resistance: Novel Checkpoints, Biomarkers, and Emerging Therapeutic Strategies
4.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
5.
Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge